Celsion +8.4% on trial data presentation


"The impressive local response rate seen in these two studies was determined by lesion measurements and digital imaging data," says Dr. Hope Rugo. "Patients are pleased with the local control in the treated areas. I look forward to continuing my involvement in the Phase 2 portion of the DIGNITY study and its future application to clinical development of ThermoDox across different cancers."

Presentation

CLSN +8.4% premarket

Comments (2)
  • Quoth the Raven
    , contributor
    Comments (2063) | Send Message
     
    It's the delivery, not the drug!
    13 Dec 2013, 09:03 AM Reply Like
  • ivansre@gmail.com
    , contributor
    Comments (3) | Send Message
     
    Hm 19.61% up at this moment. I hope that means something. I hope for my own good and the others...
    13 Dec 2013, 09:28 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs